Negotiating public health-driven licences with patent holders, sublicensing to generic manufacturers and product developers, and supporting access to those treatments in LMICs, are the core work of the Medicines Patent Pool.
Below is an overview of all our licensing and sublicensing agreements. For more information, click on the product, patent holder, generic partner or product developer you are interested in.
|LOPINAVIR, RITONAVIR (LPV/r)||100%|
|LOPINAVIR, RITONAVIR (LPV/r) PAEDIATRICS||100%|
|TENOFOVIR ALAFENAMIDE (TAF)||90.5%|
|TENOFOVIR DISOPROXIL FUMARATE (TDF)||90.5%|
|RALTEGRAVIR (RAL) PAEDIATRICS||98%|
|ABACAVIR – PAEDIATRICS (ABC)||99.3%|
|DOLUTEGRAVIR - ADULT (DTG)||94%|
|DOLUTEGRAVIR - PAEDIATRICS (DTG)||99%|